ID
45667
Description
Principal Investigator: Ann M. Moormann, University of Massachusetts Medical School, Worcester, MA, USA MeSH: Burkitt Lymphoma,Lymphoma, Non-Hodgkin https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001282 This genomic landscape of Burkitt lymphoma represents a multimodal sequencing of tumors and control tissues and individuals to better understand the etiology, and molecular pathogenesis of Burkitt lymphoma including the roles of the associated Plasmodium falciparum malaria and EBV infections. Comprehensive sequencing set includes genomic, transcriptomic, and epigenomic datasets in concert with variable clinical phenotypes and outcome information such as anatomical presentation site, in-hospital survival rates, and EBV genome type. This deposit includes additional small RNA-seq data from endemic BL (eBL) tumors and RNA-sequencing data from sorted NK cell subsets from the peripheral blood of eBL patients. The additional small RNA-seq data are from tumor specimens from 17 eBL cases, of the previously deposited polyA RNA-seq data from 28 eBL cases (phs1282.V1). The additional RNAseq data from Fluorescence-activated cell sorting (FACS) of NK cell subsets, isolated from the peripheral blood of 7 eBL cases. *For initial transcriptome analysis see: Kaymaz et al.* "Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-specific Difference." Molecular Cancer Research, 2017. PMID 28465297 *For initial microRNA analysis see: Oduor et al.* "Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma." Frontiers in Microbiology 8, 2017. PMID 28400759 *For initial NK subsets RNA expression analysis see: Forconi et al.* "A new hope for CD56negCD16pos NK cells as unconventional cytotoxic mediators: an adaptation to chronic diseases." Frontiers in Cellular and Infection Microbiology, Submitted and Under review. *For general overview of cohort study see: Buckle et al.* "Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study." Int J Cancer. 15:1231, 2016, PMID 27136063
Link
Keywords
Versions (1)
- 4/2/23 4/2/23 - Simon Heim
Copyright Holder
Ann M. Moormann, University of Massachusetts Medical School, Worcester, MA, USA
Uploaded on
April 2, 2023
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs001282 Genomics of Endemic Burkitt Lymphoma
Subject ID, sample ID, and sample use variable of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project.
- Subject ID, sample ID, and sample use variable of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project.
- Subject ID, race, sex, age at onset, and survival status in hospital of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project
- Sample ID, analyte type, body site where sample was obtained, viral genome type in tumor, viral presence in tumor, histological type of sample, tumor status of sample, NK cell subtype, primary tumor location, sample type, sequencing center, and tumor subtype of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project.
Similar models
Subject ID, sample ID, and sample use variable of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project.
- Subject ID, sample ID, and sample use variable of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project.
- Subject ID, race, sex, age at onset, and survival status in hospital of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project
- Sample ID, analyte type, body site where sample was obtained, viral genome type in tumor, viral presence in tumor, histological type of sample, tumor status of sample, NK cell subtype, primary tumor location, sample type, sequencing center, and tumor subtype of participants with endemic Burkitt lymphoma and involved in the "Pathogenesis and Immunity in Endemic Burkitt Lymphoma" project.
C1524063 (UMLS CUI [1,2])